Expression, purification and transduction of PEP-1-botulinum neurotoxin type A (PEP-1-BoNT/A) into skin

Journal of Biochemistry and Molecular Biology

Volumn 39, Issue 5, 2006, Pages 642-647

  Dae, Won Kim ^a   So, Young Kim ^a   Jae, Jin An ^a   Sun, Hwa Lee ^a   Sang, Ho Jang ^a   Moo, Ho Won ^a   Kang, Tae Cheon ^a   Chung, Kwang Hoe ^b   Jung, Hyun Ho ^c   Cho, Sung Woo ^d   Jin, Hi Choi ^e   Park, Jinseu ^a   Won, Sik Eum ^a   Soo, Young Choi ^a  

^a Hallym University   (South Korea)

^b BioBud Inc   (South Korea)

^c Medy Tox Inc   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Research Laboratory of Cell Tech Korea   (South Korea)

Author keywords

Botulinum toxin A (BoNT A); Facial wrinkles; PEP 1 peptide; Protein therapy; Protein transduction

Indexed keywords

BOTULINUM TOXIN A; DRUG DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; HYBRID PROTEIN; MERCAPTAMINE; PEP 1 PEPTIDE; PEP-1 PEPTIDE; PEPTIDE;

ANIMAL; ARTICLE; CHEMISTRY; GENETICS; HELA CELL; HUMAN; METABOLISM; MOUSE; SKIN; TOPICAL DRUG ADMINISTRATION; WESTERN BLOTTING;

ADMINISTRATION, TOPICAL; ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXIN TYPE A; CYSTEAMINE; FLUORESCEIN-5-ISOTHIOCYANATE; HELA CELLS; HUMANS; MICE; PEPTIDES; RECOMBINANT FUSION PROTEINS; SKIN;

BACTERIA (MICROORGANISMS);

EID: 33750829974     PISSN: 12258687     EISSN: 12258687     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Arnon, S. A., Schecter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine. A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Swerdlow, D. L. and Tonat, K. (2001) Botulinum toxin as a biological weapon: medical and public health management. J. Am. Med. Assoc. 285, 1059-1070.
2. Bradford, M. (1976) A rapid and sensitive method for the quantitation of microgram quantities utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
3. Carruthers, J. and Carruthers, A. (1998) The adjunctive usage of botulinum toxin. Dermatol. Surg. 24, 1244-1247.
4. Center for Disease Control (1998) Botulism in the United States, 1899-1998. Handbook for Epidemiologists, Clinnicans, and Laboratory Workers. Atlanta, Georgia US Department of Health and Human Services, Public Health Service.
5. Choi, H. S., An, J. J., Kim, S. Y., Lee, S. H., Kim, D. W., Yoo, K. Y., Won, M. H., Kang, T. C., Kwon, H. J., Kang, J. H., Cho, S. W., Kwon, O. S., Park, J., Eum, W. S. and Choi, S. Y. (2006) PEP-1-SOD fusion protein efficiently protects against paraquat-induced dopaminergic neuron in Parkinson's Disease mouse model. Free Radic. Biol. Med. In press.
6. Choi, S. H., Kim, D. W., Kim, S. Y., An, J. J., Lee, S. H., Sohn, E. J., Hwang, S. I., Won, M. H., Kang, T. C., Kwon, H. J., Kang, J. H., Cho, S. W., Park, J., Eum, W. S. and Choi, S. Y. (2005) Transduced human copper chaperone for Cu, Zn-SOD (PEP-1-CCS) protects against neuronal cell death. Mol. Cells 20, 401-408.
7. Christopher, G. W., Cieslak, T. J., Pavlin, J. A. and Eitzen Jr, E. M. (1997) Biological warfare. A historical perspective. J. Am. Med. Assoc. 278, 412-417.
8. Cordivari, C., Misra, P. V., Catania, S. and Lees, A. J. (2004) New therapeutic indications for botulinum toxins. Mov. Disord. 19, 157-161.
9. De Maio, M. (2003) Botulinum toxin in associated with other rejuvenation methods. J. Cosmetic Laser Ther. 5, 210-212.
10. Eum W. S., Choung, I. S., Li, M. Z., Kang, J. H., Kim, D. W., Park, J., Kwon, H. Y. and Choi, S. Y. (2004a) HIV-1 Tat mediated protein transduction of Cu,Zn-superoxide dismutase into pancreatic b cells in vitro and in vivo. Free Radic. Biol. Med. 37, 339-349.
11. Eum, W. S., Kim, D. W., Hwang, I. K., Yoo, K. Y., Kang, T. C., Jang, S. H., Choi, H. S., Choi, S. H., Kim, Y. H., Kim, S. Y., Kwon, H. Y., Kang, J. H., Kwon, O. S., Cho, S. W., Lee, K. S., Park, J., Won, M. H. and Choi, S. Y. (2004b) In vivo protein transduction: Biologically active intact PEP-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic. Biol. Med. 37, 1656-1669.
12. Fawell, S., Seery, J. and Daikh, Y. (1991) Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91, 664-668.
13. Ha, K. T., Lee, Y. C., Cho, S. H., Kim, J. K. and Kim, C. H. (2004) Molecular characterization of membrane type and ganglioside-specific sialidase (Neu3) expressed in E. coli. Mol. Cells 17, 267-273.
14. Hwang, J. H., Yuk, S. H., Lee, J. H., Lyoo, W. S., Ghil, S. H., Lee, S. S., Khang, I. G., Paik, S. Y. and Lee, J. Y. (2004) Differentiation of stem cells isolated from rat smooth muscle. Mol. Cells 17, 57-61.
15. Kim, C. H. (2003) A Salmonella typhimurium rfaE mutants recovers invasiveness for human epithelial cells when complemented by wild type rfaE (confering biosynthesis of ADP-L-glycero-D-manno-heptose-containing lipopolysaccharide). Mol. Cells 15, 226-232.
16. Kim, D. W., Eum, W. S., Jang, S. H., Kim, S. Y., Choi, H. S., Choi, S. H., An, J. J., Lee, S. H., Lee, K. S., Han, K., Kang, T. C., Won, M. H., Kang, J. H., Kwon, O. S., Cho, S. W., Kim, T. Y., Park, J. and Choi, S. Y. (2005) Transduced Tat-SOD fusion protein protects against ischemic brain injury. Mol. Cells 19, 88-96.
17. Kim, S. Y., An, J. J., Kim, D. W., Choi, S. H., Lee, S. H., Hwang, S. I., Kwon, O. S., Kang, T. C., Won, M. H., Cho, S. W., Park, J., Eum, W. S., Lee, K. S. and Choi, S. Y. (2006) Tat-mediated Protein Transduction of Human Brain Pyridoxine-5-P Oxidase into PC12 Cells. J. Biochem. Mol. Biol. 39, 76-83.
18. Klein, A. W. (2004) The therapeutic potential of botulinum toxin. Dermatol. Surg. 30, 452-455.
19. Lacy, B. D. and Stevens, R. C. (1999) Sequence homology and structural analysis of the clostridial neurotoxins. J. Mol. Biol. 291, 1091-1104.
20. Mauskop, A. (2002) The use of botulinum toxin in the treatment of headaches. Curr. Pain Headache Rep. 6, 320-323.
21. Mauskop, A. and Basdeo, R. (2000) Botulinum toxin A is an effective prophylactic therapy for migraines. Cephalagia 20, 422.
22. Montecucco, C. and Schiavo, G. (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13, 1-8.
23. Morris, M. C., Depollier, J., Mery, J., Heitz, F. and Divita, G. (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19, 1173-1176.
24. Oguma, K., Fujinaga, Y. and Inoue, K. (1995) Structure and function of Clostridium botulinum toxins. Microbiol. Immunol. 39, 161-168.
25. Prochiantz, A. (2000) Messenger proteins: homeoproteins, TAT and others. Curr. Opin. Cell Biol. 12, 400-406.
26. Sarrabayrouse, M. A. M. (2002) Indications and limitations for the use of botulinum toxin for the treatment of facial wrinkles. Aesth. Plast. Surg. 26, 233-238.
27. Schiavo, G., Matteoli, M. and Montecucco, C. (2000) Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766.
28. Schmidt, J. J. and Bostian, K. A. (1995) Proteolysis of synthetic peptides by type A botulinum neurotoxin. J. Protein Chem. 14, 703-708.
29. Sugiyama, H. (1980) Clostidium botulinum neurotoxin. Microbiol. Rev. 44, 419-448.
30. Verheyden, J. and Blitzer, A. (2002) Other noncosmetic uses of BOTOX. Dis. Mon. 48, 357-366.
31. Vives, E., Brodin, P. and Lebleu, B. (1997) A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010-16017.
32. Wadia, J. S. and Dowdy, S. F. (2002) Protein transduction technology. Curr. Opin. Biotechnol. 13, 52-56.
33. Wheeler, A. H. (1997) Therapeutic uses of botulinum toxin. Am. Fam. Physican 55, 541-545, 548.